Applying heart failure guidelines to adult congenital heart disease patients

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 2, 2008, Pages 165-174

  Shaddy, Robert E ^a   Webb, Gary ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adult; Congenital heart disease; Heart failure

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; INOTROPIC AGENT; NORADRENALIN; RENIN; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ADULT; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; CONGENITAL HEART DISEASE; DEFIBRILLATOR; DISEASE CLASSIFICATION; EVIDENCE BASED PRACTICE; EXERCISE TOLERANCE; FONTAN PROCEDURE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART SINGLE VENTRICLE; HORMONAL REGULATION; HUMAN; MORTALITY; MYOCARDIAL DISEASE; PRACTICE GUIDELINE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; CARDIOVASCULAR SYSTEM; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; HEART VENTRICLE; HEART VENTRICLE FUNCTION; METABOLISM; PATHOPHYSIOLOGY; REVIEW;

ADULT; BIOLOGICAL MARKERS; CARDIOVASCULAR SYSTEM; HEART DEFECTS, CONGENITAL; HEART FAILURE; HEART VENTRICLES; HUMANS; NEUROTRANSMITTER AGENTS; PRACTICE GUIDELINES AS TOPIC; VENTRICULAR FUNCTION;

EID: 40149107197     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.2.165     Document Type: Article

References (62)

1. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult - Summary Article. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol. 46(6), 1116-1143 (2005).
2. Swedberg K, Cleland J, Dargie H et al. Diagnosis and treatment of chronic heart disease. Guidelines of the European Society of Cardiology. Revision 2005. Kardiol. Pol. 63(5), 509-543; discussion 544-508 (2005).
3. Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Rev. Esp. Cardiol. 58(9), 1062-1092 (2005).
4. Redington AN. Determinants and assessment of pulmonary regurgitation in tetralogy of Fallot: practice and pitfalls. Cardiol. Clin. 24(4), 631-639, vii (2006).
5. Sigurdsson A, Amtorp O, Gundersen T, Nilsson B, Remes J, Swedberg K. Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group. Br. Heart J. 72(5), 422-427 (1994).
6. Wei CM, Lerman A, Rodeheffer RJ et al. Endothelin in human congestive heart failure. Circulation 89(4), 1580-1586 (1994).
7. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am. J. Cardiol. 41(2), 233-243 (1978).
8. Eriksson SV, Eneroth P, Kjekshus J, Offstad J, Swedberg K. Neuroendocrine activation in relation to left ventricular function in chronic severe congestive heart failure: a subgroup analysis from the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Clin. Cardiol. 17(11), 603-606 (1994).
9. Cohn JN, Levine TB, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med. 311(13), 819-823 (1984).
10. Pousset F, Isnard R, Lechat P et al. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur. Heart J. 18(2), 254-258 (1997).
11. Metra M, Nodari S, D'Aloia A et al. Effects of neurohormonal antagonism on symptoms and quality-of-life in heart failure. Eur. Heart J. 19(Suppl. B), B25-B35 (1998).
12. Eichhorn EJ. Prognosis determination in heart failure. Am. J. Med. 110(Suppl. 7A), 14S-36S (2001).
13. Bolger AP, Sharma R, Li W et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 106(1), 92-99 (2002).
14. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N. Engl. J. Med. 316(23), 1429-1435 (1987).
15. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N. Engl. J. Med. 325(5), 293-302 (1991).
16. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. 327(10), 669-677 (1992).
17. Bristow MR. β-adrenergic receptor blockade in chronic heart failure. Circulation 101(5), 558-569 (2000).
18. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341(10), 709-717 (1999)
19. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348(14), 1309-1321 (2003)
20. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353(9146), 9-13 (1999).
21. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353(9169), 2001-2007 (1999).
22. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344(22), 1651-1658 (2001).
23. Packer M, Fowler MB, Roecker EB et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106(17), 2194-2199 (2002).
24. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357(9266), 1385-1390 (2001).
25. Puley G, Siu S, Connelly M et al. Arrhythmia and survival in patients > 18 years of age after the mustard procedure for complete transposition of the great arteries. Am. J. Cardiol. 83(7), 1080-1084 (1999).
26. Kirjavainen M, Happonen JM, Louhimo I. Late results of Senning operation. J. Thorac. Cardiovasc. Surg. 117(3), 488-495 (1999).
27. Piran S, Veldtman G, Siu S, Webb GD, Liu PP. Heart failure and ventricular dysfunction in patients with single or systemic right ventricles. Circulation 105(10), 1189-1194 (2002).
28. Hurwitz RA, Caldwell RL, Girod DA, Brown J. Right ventricular systolic function in adolescents and young adults after Mustard operation for transposition of the great arteries. Am. J. Cardiol. 77(4), 294-297 (1996).
29. Beauchesne LM, Warnes CA, Connolly HM, Ammash NM, Tajik AJ, Danielson GK. Outcome of the unoperated adult who presents with congenitally corrected transposition of the great arteries. J. Am. Coll. Cardiol. 40(2), 285-290 (2002).
30. Graham TP Jr, Bernard YD, Mellen BG et al. Long-term outcome in congenitally corrected transposition of the great arteries: a multi-institutional study. J. Am. Coll. Cardiol. 36(1), 255-261 (2000).
31. Dodge-Khatami A, Tulevski II, Bennink GB et al. Comparable systemic ventricular function in healthy adults and patients with unoperated congenitally corrected transposition using MRI dobutamine stress testing. Ann. Thorac. Surg. 73(6), 1759-1764 (2002).
32. Eicken A, Fratz S, Gutfried C et al. Hearts late after fontan operation have normal mass, normal volume, and reduced systolic function: a magnetic resonance imaging study. J. Am. Coll. Cardiol. 42(6), 1061-1065 (2003).
33. Giardini A, Lovato L, Donti A et al. Relation between right ventricular structural alterations and markers of adverse clinical outcome in adults with systemic right ventricle and either congenital complete (after Senning operation) or congenitally corrected transposition of the great arteries. Am. J. Cardiol. 98(9), 1277-1282 (2006).
34. Bos JM, Hagler DJ, Silvilairat S et al. Right ventricular function in asymptomatic individuals with a systemic right ventricle. J. Am. Soc. Echocardiogr. 19(8), 1033-1037 (2006).
35. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 105(11), 1387-1393 (2002).
36. Fredriksen PM, Veldtman G, Hechter S et al. Aerobic capacity in adults with various congenital heart diseases. Am. J. Cardiol. 87(3), 310-314 (2001).
37. Norozi K, Wessel A, Alpers V et al. Incidence and risk distribution of heart failure in adolescents and adults with congenital heart disease after cardiac surgery. Am. J. Cardiol. 97(8), 1238-1243 (2006).
38. Diller GP, Dimopoulos K, Okonko D et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation 112(6), 828-835 (2005).
39. Norozi K, Wessel A, Alpers V et al. Chronotropic incompetence in adolescents and adults with congenital heart disease after cardiac surgery. J. Card. Fail. 13(4), 263-268 (2007).
40. Kavey RE, Allada V, Daniels SR et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 114(24), 2710-2738 (2006).
41. Roberts WC. Major anomalies of coronary arterial origin seen in adulthood. Am. Heart J. 111(5), 941-963 (1986).
42. Gagliardi MG, Adorisio R, Crea F, Versacci P, Di Donato R, Sanders SP. Abnormal vasomotor function of the epicardial coronary arteries in children five to eight years after arterial switch operation: an angiographic and intracoronary Doppler flow wire study. J. Am. Coll. Cardiol. 46(8), 1565-1572 (2005).
43. Cowley CG, Orsmond GS, Feola P, McQuillan L, Shaddy RE. Long-term, randomized comparison of balloon angioplasty and surgery for native coarctation of the aorta in childhood. Circulation 111(25), 3453-3456 (2005).
44. McElhinney DB, Petrossian E, Tworetzky W, Silverman NH, Hanley FL. Issues and outcomes in the management of supravalvar aortic stenosis. Ann. Thorac. Surg. 69(2), 562-567 (2000).
45. Lewis AB, Heymann MA, Stanger P, Hoffman JI, Rudolph AM. Evaluation of subendocardial ischemia in valvar aortic stenosis in children. Circulation 49(5), 978-984 (1974).
46. Moons P, Van Deyk K, Dedroog D, Troost E, Budts W. Prevalence of cardiovascular risk factors in adults with congenital heart disease. Eur. J. Cardiovasc. Prev. Rehabil. 13(4), 612-616 (2006).
47. Bonow RO, Carabello B, de Leon AC Jr et al. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation 98(18), 1949-1984 (1998).
48. Lester SJ, McElhinney DB, Viloria E et al. Effects of losartan in patients with a systemically functioning morphologic right ventricle after atrial repair of transposition of the great arteries. Am. J. Cardiol. 88(11), 1314-1316 (2001).
49. Kouatli AA, Garcia JA, Zellers TM, Weinstein EM, Mahony L. Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation 96(5), 1507-1512 (1997).
50. Hechter SJ, Fredriksen PM, Liu P et al. Angiotensin-converting enzyme inhibitors in adults after the Mustard procedure. Am. J. Cardiol. 87(5), 660-663, A611 (2001).
51. Dore A, Houde C, Chan KL et al. Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricles: a multicenter, randomized, placebo-controlled clinical trial. Circulation 112(16), 2411-2416 (2005).
52. Derrick G, Deanfield JE. Decline in ventricular function and clinical condition after Mustard repair. Eur. Heart J. 25(21), 1863-1864 (2004).
53. Derrick GP, Josen M, Vogel M, Henein MY, Shinebourne EA, Redington AN. Abnormalities of right ventricular long axis function after atrial repair of transposition of the great arteries. Heart 86(2), 203-206 (2001).
54. Vogel M, Derrick G, White PA et al. Systemic ventricular function in patients with transposition of the great arteries after atrial repair: a tissue Doppler and conductance catheter study. J. Am. Coll. Cardiol. 43(1), 100-106 (2004).
55. Josephson CB, Howlett JG, Jackson SD, Finley J, Kells CM. A case series of systemic right ventricular dysfunction post atrial switch for simple D-transposition of the great arteries: the impact of β-blockade. Can. J. Cardiol. 22(9), 769-772 (2006).
56. Giardini A, Lovato L, Donti A et al. A pilot study on the effects of carvedilol on right ventricular remodelling and exercise tolerance in patients with systemic right ventricle. Int. J. Cardiol. (2006).
57. Doughan AR, McConnell ME, Book WM. Effect of β blockers (carvedilol or metoprolol XL) in patients with transposition of great arteries and dysfunction of the systemic right ventricle. Am. J. Cardiol. 99(5), 704-706 (2007).
58. Cleland JG, Daubert JC, Erdmann E et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med. 352(15), 1539-1549 (2005).
59. Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. 352(3), 225-237 (2005).
60. Yap SC, Roos-Hesselink JW, Hoendermis ES et al. Outcome of implantable cardioverter defibrillators in adults with congenital heart disease: a multi-centre study. Eur. Heart J. 28(15), 1854-1861 (2007).
61. Bernstein D, Naftel D, Chin C et al. Outcome of listing for cardiac transplantation for failed Fontan: a multi-institutional study. Circulation 114(4), 273-280(2006).
62. Coskun O, Coskun T, El-Arousy M et al. Heart transplantation in adults with congenital heart disease: experience with 15 patients. Asaio J. 53(1), 103-106 (2007).